FSCN1 and breast carcinoma: The retrospective nature of this study and the underrepresentation of specific molecular subtypes further highlight the need for prospective, multicenter validation studies to confirm these observations and refine the prognostic and predictive value of fascin and TOP2A alterations in breast cancer.